Armored Inducible Expression of IL-12 Enhances Antitumor Activity of Glypican-3–Targeted Chimeric Antigen Receptor–Engineered T Cells in Hepatocellular Carcinoma-Reference-Cited by-同舟云学术

Armored Inducible Expression of IL-12 Enhances Antitumor Activity of Glypican-3–Targeted Chimeric Antigen Receptor–Engineered T Cells in Hepatocellular Carcinoma

Published:2019-05-29 Issue:1 Volume:203 Page:198-207
ISSN:0022-1767
Container-title:The Journal of Immunology
language:en
Short-container-title:J.I.

Author:

Liu Ying,Di Shengmeng,Shi Bizhi,Zhang Honghong,Wang Yi,Wu Xiuqi,Luo Hong,Wang Huamao,Li Zonghai^ORCID,Jiang Hua^ORCID

Publisher

The American Association of Immunologists

Subject

Immunology,Immunology and Allergy

Reference63 articles.

1. Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis

2. Hepatocellular Carcinoma Incidence, Mortality, and Survival Trends in the United States From 1975 to 2005

3. Strategies for Safer Liver Surgery and Partial Liver Transplantation

4. Hepatocellular carcinoma review: Current treatment, and evidence-based medicine

5. Cancer Immunotherapy

Cited by 102 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Astragalus polysaccharide enhances antitumoral effects of chimeric antigen receptor- engineered (CAR) T cells by increasing CD122+CXCR3+PD-1- memory T cells;Biomedicine & Pharmacotherapy;2024-10

2. Multi-armored allogeneic MUC1 CAR T cells enhance efficacy and safety in triple-negative breast cancer;Science Advances;2024-08-30

3. Mesothelin CAR-T cells expressing tumor-targeted immunocytokine IL-12 yield durable efficacy and fewer side effects;Pharmacological Research;2024-05

4. Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors;Cancer Cell International;2024-04-15

5. Adoptive cell therapy for solid tumors beyond CAR-T: Current challenges and emerging therapeutic advances;Journal of Controlled Release;2024-04